Effects of Faecal Microbiota Transplantation in Patients With IBS

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-01

Study Completion Date

2019-05-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Irritable bowel syndrom (IBS) is a common chronic gastrointestinal disorder that affects 10-20% of the world population. The prevalence of IBS in Norway is between 8% and 25%. The pathophysiology of IBS is incompletely understood, and there is no effective treatment for this condition. Imbalance (dysbiosis) of the gut microbiome has been found in patients with IBS. In the absence of effective method to restore the dysbiosis, transplantation of a microbiome from healthy individuals with well-functioning gut (FMT) to those with IBS has been performed. Two randomized double blind placebo-controlled (RCT) studies have been published recently. Whereas it was reported in one study that FMT reduced symptom and improved quality of life in patients with IBS, FMT had no effect in the other study. In order to clarify these contradictory results, a new RCT study that enrolled larger number of patients is required. In this study, the investigators intend to recruit 170 IBS patients from those attending outdoor clinic at Stord hospital in a randomized, double blind placebo trial. A single healthy donor with well-characterized microbiome is going to be used. The effects on symptoms, quality of life, fatigue as well as dysbiosis before and after FMT are going to be investigated. The possible mechanisms behind the effects if any of FMT such as changes in intestinal stem cells, enteroendocrine cells and local immune defense shall be also investigated. The patients are going to be randomized either to placebo (own faces), 30 g or 60 g of the donor faces in ratio 1:1:1.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Fecal Transplantation in Patients With IBS

NCT03333291

IBS - Irritable Bowel Syndrome

COMPLETED NA

Donor Versus Autologous Fecal Microbiota Transplantation for Irritable Bowel Syndrome

NCT04691544

Irritable Bowel Syndrome

ACTIVE_NOT_RECRUITING PHASE3

Faecal Microbiota Transplantation (FMT) in Patients With IBSmechanism(s) of Action

NCT04236843

Irritable Bowel Syndrome

COMPLETED NA

Donor Selection for Faecal Microbiota Transplantation in Irritable Bowel Syndrome

NCT06171126

Irritable Bowel Syndrome

ACTIVE_NOT_RECRUITING NA

Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome

NCT02092402

Irritable Bowel Syndrome (IBS)

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study design Patients One hundred and seventy patients who fulfill the following inclusion criteria and lack the exclusion criteria shall be included. In addition, the patients are examined physically, and blood tests are taken to exclude inflammation, and liver, kidney and thyroid diseases. They undergo further gastroscopy with duodenal biopsies to exclude coeliac disease. They undergo also colonoscopy to exclude malignity, or inflammatory bowel disease (IBD). Microscopic colitis is excluded by examining tissue obtained by colonoscopy with segmental biopsy sampling.

Donor selection and screening:

A single donor shall be selected and screened according to the European and international guidelines. The donor should not be a first-degree relative to any of the patients, as the intestinal microbiota is affected by the genetic composition, and similarity between the donor and recipient in the fecal microbiota may occur.

Protocol

Feces collection, preparation and administration:

Feces from both the donors and recipients were collected and stored at - 80•. Frozen feces (30 or 60g) from the donor or patients (placebo), thawed at 5° C and were dissolved in 50 mL of 0.9% sterile saline per 30 g feces. The dissolved stool is administrated to the patients, after overnight fast, through working channel of gastroduodeno-scope in pars descendent duodenum distal to the papilla of Vater.

Sigmoidoscopy: After administration of faeces, a sigmoidoscopy is performed during which 4 biopsies from the sigmoid colon about 30 cm from anus, and 4 biopsies from the rectum about 15 cm from anus are taken. Sigmoidoscopy is repeated in the same way 1 month after FMT.

Methods Questionnaires

1. IBS symptom severity Scale (IBS-SSS) questionnaire.
2. Birmingham Symptom scale questionnaires.
3. IBSQoL questionnaire.
4. Short form of Nepean Dyspepsia Index (SF-NDI) questionnaire.
5. Fatigue Assessment Scale (FAS).

Microbiome analysis Gut microbiota analysis was performed using the GA-mapTM Dysbiosis test (Genetic Analysis AS, Oslo, Norway) by algorithmically assessing fecal bacterial abundance and profile (dysbiosis index, DI), and potential deviation in the microbiome from normobiosis. GA-map test is based on fecal homogenization, mechanical bacterial cell disruption and automated total bacterial genomic DNA extraction using magnetic beads. DI is based on 54 DNA probes targeting more than 300 bacterial strains based on their 16S rRNA sequence in seven variable regions (V3-V9). Twenty-six bacteria probes are species specific, 19 detect bacteria on genus level, and 9 probes detect bacteria at higher taxonomic levels. Probe labeling is by single nucleotide extension and hybridization to complementary probes coupled to magnetic beads, and signal detection by using Bio Code 1000A 128-Plex Analyzer (Applied Bio Code, Santa Fe Springs, CA, USA). A DI above 2 shows a microbiota profile that differs from that of the normobiotic reference collection (DI 1-2: non-dysbiosis, DI: moderate, DI 4-5: severe dysbiosis).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Intervention. Dietary supplement: fecal suspension. Healthy donor or own faeces (placebo) administrated through working canal of a gastroscope.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

A research nurse, not involved in the trial, create the allocation sequence using a website. This was done in blocks of 21 patients.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Patients receive suspension of their own feces.

Group Type NO_INTERVENTION

No interventions assigned to this group

30 g donor dose

Patients receiving 30 g of a healthy donor feces.

Group Type ACTIVE_COMPARATOR

healthy feces microbiota

Intervention Type DIETARY_SUPPLEMENT

Suspension of healthy feces microbiota in sterile saline solution

60 g donor dose

Patients receiving 60 g of a healthy donor feces.

Group Type ACTIVE_COMPARATOR

healthy feces microbiota

Intervention Type DIETARY_SUPPLEMENT

Suspension of healthy feces microbiota in sterile saline solution

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

healthy feces microbiota

Suspension of healthy feces microbiota in sterile saline solution

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients between who fulfill Rome IV criteria for the diagnosis of IBS.
2. Patients with moderate to severe IBS symptoms (IBS-SSS ≥ 175).

Exclusion Criteria

1. Pregnant, planning pregnancy or lactating women.
2. The use of antibiotics or probiotics within 1 month prior to FMT.
3. Patients who had undergone any abdominal surgery, with the exception of appendectomy, cholecystectomy, Caesarean section or hysterectomy.

Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No